Tevadaptor - Closed drug reconstitution system ישראל - עברית - Ministry of Health

tevadaptor - closed drug reconstitution system

teva medical ltd. - migada - אחות - see attached document : us fda 510(k) k051669 approved indications for use

טרזוסין טבע    5 מג ישראל - עברית - Ministry of Health

טרזוסין טבע 5 מג

teva israel ltd - terazosin as hydrochloride dihydrate - טבליה - terazosin as hydrochloride dihydrate 5 mg - terazosin

טבעגרסטים ישראל - עברית - Ministry of Health

טבעגרסטים

teva israel ltd - filgrastim - תמיסה להזרקה\אינפוזיה - filgrastim 0.6 mg/ml - filgrastim - filgrastim - tevagrastim is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. the safety and efficacy of tevagrastim are similar in adults and children receiving cytotoxic chemotherapy. tevagrastim is indicated for the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc). in patients children or adults with severe congenital neutropenia cyclic or idiopathic neutropenia with an absolute nuetrophil count (anc) less than or equal to 0.5 x 1000000000 /l and a history of severe or recurrent infections long term administration of tevagrastim is indicated to increase neutophil count and to red

טבעקוטן ישראל - עברית - Ministry of Health

טבעקוטן

teva israel ltd - clotrimazole; dexamethasone acetate; neomycin sulfate - קרם - clotrimazole 1 %; dexamethasone acetate 0.044 %; neomycin sulfate 0.645 % - dexamethasone - dexamethasone - tevacutan is indicated for the treatment of mycotic infections of the skin complicated by inflammation and/or secondary infection.

סימבסטאטין טבע 20 מג ישראל - עברית - Ministry of Health

סימבסטאטין טבע 20 מג

teva israel ltd - simvastatin - טבליה - simvastatin 20 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to thes

סימבסטאטין טבע 10 מג ישראל - עברית - Ministry of Health

סימבסטאטין טבע 10 מג

teva israel ltd - simvastatin - טבליה - simvastatin 10 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures.- reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios.homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these

סימבסטאטין טבע 80 מג ישראל - עברית - Ministry of Health

סימבסטאטין טבע 80 מג

teva israel ltd - simvastatin - טבליה - simvastatin 80 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: reduce the risk of total mortality by reducing coronary death reduce the risk of non-fatal myocardial infarction reduce the risk for undergoing myocardial revascularization procedures.reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measure

סימבסטאטין טבע   40 מג ישראל - עברית - Ministry of Health

סימבסטאטין טבע 40 מג

teva israel ltd - simvastatin - טבליה - simvastatin 40 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: reduce the risk of total mortality by reducing coronary death ;reduce the risk of non-fatal myocardial infarction ;reduce the risk for undergoing myocardial revascularization procedures. reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these meas

פליפרידון טבע  100 מג ישראל - עברית - Ministry of Health

פליפרידון טבע 100 מג

teva israel ltd - paliperidone palmitate - תרחיף להזרקה - שחרור נרחב - paliperidone palmitate 100 mg / 1 ml - paliperidone

פליפרידון טבע  150 מג ישראל - עברית - Ministry of Health

פליפרידון טבע 150 מג

teva israel ltd - paliperidone as palmitate - תרחיף להזרקה - שחרור נרחב - paliperidone as palmitate 100 mg / 1 ml - paliperidone